Genome&Company (KRX: 314130)
Who is buying Genome&Company?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩2.3bn ($2M) of Genome&Company, the 170th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net sold ₩3.3bn ($2M) and retail investors net bought ₩7.2bn ($5M) over the same window. Foreigners were net buyers on 4 of the 20 sessions.
Foreign investors hold 2.5% of Genome&Company's listed shares (KRX ownership data as of Oct 13, 2026), down from 3.71% twenty sessions earlier and 2.84% a year ago.
The stock closed at ₩4,880 on Oct 13, 2026: +44.81% over 20 sessions, -29.07% year-to-date, +72.74% over one year. The 52-week range is ₩2,585 – ₩10,180.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩4,880 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-10-12 | ₩5,170 | ₩-0.4bn | ₩-0.1bn | +₩0.5bn |
| 2026-10-08 | ₩5,470 | ₩-0.0bn | ₩-0.5bn | +₩0.6bn |
| 2026-10-07 | ₩5,320 | ₩-0.6bn | ₩-0.8bn | +₩1.5bn |
| 2026-10-06 | ₩5,880 | +₩0.4bn | ₩-0.9bn | +₩0.7bn |
| 2026-10-02 | ₩5,500 | ₩-0.2bn | ₩-0.5bn | +₩0.8bn |
| 2026-10-01 | ₩5,390 | ₩-0.1bn | ₩-0.3bn | +₩0.5bn |
| 2026-09-30 | ₩5,100 | +₩0.2bn | ₩-0.3bn | +₩0.6bn |
| 2026-09-29 | ₩4,490 | ₩-0.2bn | +₩0.1bn | +₩0.3bn |
| 2026-09-28 | ₩4,645 | ₩-0.2bn | ₩-0.1bn | +₩0.3bn |
| 2026-09-23 | ₩4,835 | ₩-0.3bn | +₩0.0bn | +₩0.5bn |
| 2026-09-22 | ₩4,230 | ₩-0.0bn | ₩-0.0bn | +₩0.3bn |
| 2026-09-21 | ₩3,990 | +₩0.7bn | ₩-0.0bn | ₩-0.7bn |
| 2026-09-18 | ₩3,395 | ₩-0.1bn | +₩0.1bn | ₩-0.0bn |
| 2026-09-17 | ₩3,515 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-16 | ₩3,330 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-09-15 | ₩3,405 | ₩-1.2bn | +₩0.1bn | +₩1.1bn |
| 2026-09-14 | ₩3,175 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-11 | ₩3,250 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-09-10 | ₩3,300 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-09 | ₩3,370 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-08 | ₩3,285 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-09-07 | ₩3,445 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-04 | ₩3,435 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-03 | ₩3,350 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-02 | ₩3,480 | ₩-0.2bn | +₩0.0bn | +₩0.1bn |
| 2026-09-01 | ₩3,810 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-08-31 | ₩3,755 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-28 | ₩3,815 | ₩-0.2bn | +₩0.0bn | +₩0.3bn |
| 2026-08-27 | ₩3,985 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-08-26 | ₩4,045 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-08-25 | ₩4,075 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-24 | ₩4,240 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-08-21 | ₩4,205 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-20 | ₩4,415 | ₩-0.4bn | ₩-0.0bn | +₩0.4bn |
| 2026-08-19 | ₩4,230 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-18 | ₩4,230 | ₩-0.5bn | ₩-0.0bn | +₩0.5bn |
| 2026-08-14 | ₩4,620 | ₩-0.4bn | +₩0.0bn | +₩0.4bn |
| 2026-08-13 | ₩4,460 | ₩-0.4bn | ₩0.0bn | +₩0.4bn |
| 2026-08-12 | ₩4,430 | ₩-0.4bn | ₩0.0bn | +₩0.4bn |
| 2026-08-11 | ₩4,190 | +₩0.1bn | ₩-0.4bn | +₩0.6bn |
| 2026-08-10 | ₩4,160 | +₩1.7bn | ₩-0.7bn | +₩2.7bn |
| 2026-08-07 | ₩3,630 | +₩0.2bn | +₩0.0bn | +₩0.3bn |
| 2026-08-06 | ₩3,600 | ₩-0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-08-05 | ₩3,580 | ₩-0.0bn | +₩0.1bn | +₩0.5bn |
| 2026-08-04 | ₩3,650 | ₩-0.1bn | ₩-0.0bn | +₩0.5bn |
| 2026-08-03 | ₩3,455 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-07-31 | ₩3,280 | +₩0.4bn | +₩0.1bn | ₩-0.4bn |
| 2026-07-30 | ₩2,990 | +₩0.1bn | ₩-0.1bn | ₩-0.0bn |
| 2026-07-29 | ₩3,100 | +₩0.7bn | +₩0.1bn | ₩-0.7bn |
| 2026-07-28 | ₩3,565 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-27 | ₩3,800 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-07-24 | ₩3,730 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-23 | ₩4,095 | ₩-0.1bn | +₩0.0bn | +₩0.2bn |
| 2026-07-22 | ₩3,850 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-21 | ₩3,540 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-20 | ₩3,480 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-07-16 | ₩3,625 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-07-15 | ₩3,880 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-07-14 | ₩3,590 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-07-13 | ₩3,935 | ₩-0.1bn | ₩-0.0bn | +₩0.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.0bn | $-0M | ₩-0.0bn | +₩0.1bn |
| 5 days | ₩-0.6bn | $-0M | ₩-2.4bn | +₩3.3bn |
| 20 days | ₩-2.3bn | $-2M | ₩-3.3bn | +₩7.2bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Genome&Company stock?
Over the last 5 sessions foreign investors net sold ₩0.6bn ($0M) of Genome&Company; over 60 sessions they net sold ₩3.6bn ($3M); since Jan 1, 2026 they net bought ₩1.0bn ($1M). Over 20 sessions the stock is the 170th largest foreign net sale among 1828 KOSDAQ stocks.
How much of Genome&Company do foreign investors own?
Foreign investors own 2.5% of Genome&Company's shares as of Oct 13, 2026, versus 2.84% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩3.3bn ($2M) and retail investors net bought ₩7.2bn ($5M) of Genome&Company. Retail investors have been absorbing what foreigners and institutions are selling.
Is Genome&Company listed on KOSPI or KOSDAQ?
Genome&Company (지놈앤컴퍼니) trades on KOSDAQ under KRX code 314130 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.2B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩14bn ($11M) | – | -₩55bn (-$41M) | -₩51bn (-$38M) |
| 2024 | ₩28bn ($21M) | +94.10% | -₩24bn (-$18M) | -₩27bn (-$20M) |
| 2025 | ₩25bn ($18M) | -11.40% | -₩29bn (-$22M) | -₩8bn (-$6M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.